Co-Chairpersons' Welcome and Opening Remarks

Peter Kramer, PhD, Senior Director, External Science, Technology & Licensing, BRISTOL-MYERS SQUIBB
Vik Seoni, Vice President, Business Development, ENDO PHARMACEUTICALS

How Are We Creating Sustainable Business Models Out of Evolving Technology Companies?

Moderator:
Cynthia Robbins-Roth, Featured Columnist, BIOWORLD TODAY

Panelists:
Michael Step, SVP Corporate Development, SANTARUS
Peter Stein, Chief Executive Officer, NORGINE
James Gale, Managing Partner, SANDERS MORRIS HARRIS
Bridget Hage, Manager, Business Development, 3M DRUG DELIVERY SYSTEMS

Growth Opportunities for Drug Delivery Systems: Development Trends for New Drugs in the Pipeline

Joseph A. DiMasi, PhD., Director of Economic Analysis, TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

The Annual Wall St Address with David M. Steinberg: Sector Trends, Key Technologies to Watch, and Predictions for the Future

David M. Steinberg, Managing Director, Equity Research, Specialty Pharmaceuticals and Drug Delivery, DEUTSCHE BANK

Washington Update 2007

Steve Usdin, Senior Editor, BIOCENTURY

Track Chair:

Edward Tuttle
Managing Principal
ANALYSIS GROUP

Track Chair:

Clifford M Davidson
Partner
DAVIDSON, DAVIDSON & KAPPEL, LLC

Track Chair:

Paul Burke
Director of Pharmaceutics
AMGEN

1:30 | Structuring Your Deals Creatively to Achieve the Strategic Goals of All Parties

Moderator:
Allen Downs, Senior Executive Director, Licensing & Business Development, PURDUE

Panelists:
Jason Levin, Executive Director, Licensing & Acquisitions, JAZZ PHARMACEUTICALS

Don Reed, ELAN DRUG TECHNOLOGIES

Tim Duffy, Executive Vice President, Marketing & Business Development , NASTECH PHARMACEUTICAL COMPANY

Jeff D. Davis, Head, Global New Business Development, P&G PHARMACEUTICALS

1:30 | Pharmaceutical Life-Cycle Management Strategies to Maintain and Extend a Franchise's Life Cycle: Patents and Beyond

Timothy X. Witkowski, Director and Senior Counsel, Intellectual Property , BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

1:30 | Use of Controlled Release Technologies for the Development of Drugs Exhibiting pH Dependent Solubility in the GI Tract

Troy M. Harmon, M.S., MBA, Senior Director, Business Development, EURAND

2:15 | Collaborating Effectively to Mitigate Risk and Safeguard Your Interests

Moderator:
Mark Coflin, Global Executive Director, Alliance Management, Global Business Development & Licensing, NOVARTIS

Panelists:
Michael Flakus, Sr. Principal, Strategic Alliances, PFIZER

Barry Cohen, VP Business Development, NOVADEL

Willie Quinn, Director Licensing & Acquisitions, JAZZ PHARMACEUTICALS

Christian Pangratz, Associate Director, Strategic Alliances & Business Development, NEKTAR THERAPEUTICS

2:15 | Understand the Potential Pitfalls Before You Go Down the 505 (b)(2) NDA Route

Vickie O'Neill, Vice President, Research and Technology Development, UPSHER-SMITH LABORATORIES

Shashank Upadhye, Vice President, Head of Intellectual Property, SANDOZ US-NOVARTIS CORP.

2:00-2:30 | Cutting-Edge Technology Showcase

Moderated by:
Peter Hoffman, Vice President, Technology Development, GENZYME PHARMACEUTICALS

Confirmed Panelists:
Eric Tomlinson PhD DSc, President and Chief Executive Officer, ALTEA THERAPEUTICS

Dr, Helmut Knoller, FRESNIUS KABI

2:30 | NanoCrystal® Technology – Clinical Benefits & Commercial Opportunities

Elaine Liversidge, ELAN DRUG TECHNOLOGIES

KEYNOTE PRESENTATION

Create and Sustain a Competitive Advantage by Identifying & Utilizing Undervalued Assets

A favorite speaker amongst the venture capital community, Billy Beane, General Manager of the Oakland Athletics and the subject of the best selling book, "Moneyball" shares his own approach to innovation in management. His approach is a stunningly successful example of identifying undervalued assets and using these to create and sustain a competitive advantage, teaching you how to re-invent the rules of your own corporate game.